Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization
Metrics: PDF 849 views | Full Text 1276 views | ?
Lieselotte Lemoine1,2, Elsy Thijssen3, Robert Carleer3, Jirka Cops1,4, Veerle Lemmens5, Peter Van Eyken6, Paul Sugarbaker7 and Kurt Van der Speeten1,2
1Department of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
2Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Genk, Belgium
3Department of Applied and Analytical Chemistry, Institute for Materials Research (IMO), Hasselt University, Diepenbeek, Belgium
4Department of Medicine and Life Sciences, Biomedical Research Institute, Rehabilitation Research Center, Hasselt University, Hasselt, Belgium
5Department of Medicine and Life Sciences, Dynamic Bioimaging Laboratory, Advanced Optical Microscopy Centre, Biomedical Research Institute (BIOMED), Hasselt University, Hasselt, Belgium
6Department of Pathology, Ziekenhuis Oost-Limburg, Genk, Belgium
7Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, DC, USA
Lieselotte Lemoine, email: email@example.com
Keywords: peritoneal surface malignancy; colorectal cancer; HIPEC; oxaliplatin; dosimetry
Received: November 24, 2018 Accepted: January 28, 2019 Published: February 15, 2019
Worldwide, cytoreductive surgery (CRS) and hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) are used in current clinical practice for colorectal peritoneal surface malignancy (PSM) treatment. Although, there is an acknowledged standardization regarding the CRS, we are still lacking a much-needed standardization amongst the various intraperitoneal (IP) chemotherapy protocols, including the HIPEC dosing regimen. We should rely on pharmacologic evidence building towards such a standardization. The current IP chemotherapy dosing regimens can be divided into body surface area (BSA)-based and concentration-based protocols. A preclinical animal study was designed to evaluate pharmacologic advantage (PA), efficacy and survival. WAG/Rij rats were IP injected with the rat colonic carcinoma cell line CC-531. Animals were randomized into three groups: CRS alone or CRS combined with oxaliplatin-based HIPEC (either BSA- or concentration-based). There was no difference in PA between the two groups (p=0.283). Platinum concentration in the tumor nodule was significantly higher in the concentration-based group (p<0.001). Median survival did not differ between the treatment groups (p<0.250). This preclinical study, in contrast to previous thinking, clearly demonstrates that the PA does not provide any information about the true efficacy of the drug and emphasizes the importance of the tumor nodule as pharmacologic endpoint.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.